# Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

> **NCT00003568** · PHASE2 · COMPLETED · sponsor: **University of Illinois at Chicago**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** incomplete Freund's adjuvant

## Key facts

- **NCT ID:** NCT00003568
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-11
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003568, "Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00003568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*